|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Humoral hypercalcemia of malig- nancy caused by parathyroid hormone-related peptlde-secreting neuroendocrine tumors: report of six cases 显示文摘 | Milanesi A Yu R Wolin EM | 2013 | Pancreatology2013，13，3： | 1 |
| 2 | PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors 显示文摘 | Wolin EM | 2013 | Cancer Lett2013，335，1： | 1 |
| 3 | Multivariate analysis including biomarkers in the phase Ⅲ RADIANT-2 study of oc- treotide LAR plus everolimus or placebo among patients with advanced neuroendocrine tumors (abstract)显示文摘 | Yao JC Hainsworth JD Wolin EM | 2012 | J Clin Oneol2012，30，4： | 1 |
| 4 | The expanding role of sormtostatin analogs in the management of neuroendocrine tumors显示文摘 | Wolin EM | 2012 | Gastrointest Cancer IRes2012，5，5： | 1 |
| 5 | PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors显示文摘 | Wolin EM | 2013 | Cancer Lett2013，335，1： | 1 |
| 6 | Safety,tolerability,pharmacokinetics,and pharmacodynamics of a long-acting release (LAR)formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors:results from a randomized,multicenter,open-label,phase Ⅰ study显示文摘 | Wolin EM Hu K Hughes G | 2013 | Cancer Chemother Pharmacol2013，72，2： | 1 |
| 7 | Safety,tolerability,pharmacokinetics,and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors:results from a randomized,multicenter,open-label,phase Ⅰ study显示文摘 | Wolin EM Hu K Hughes G | 2013 | Cancer Chemother Pharmacol2013，72，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员